What does NeoGenomics company do?
NeoGenomics is a premier cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers in their pursuit of providing better futures for people living with cancer.
Who owns NeoGenomics?
Douglas M. VanOort
NeoGenomics
| Type | Public |
|---|---|
| Founded | 2002 |
| Headquarters | Fort Myers, Florida , United States |
| Area served | Worldwide |
| Key people | Douglas M. VanOort (Chairman and CEO) |
When did NeoGenomics acquire clarinet?
Dec. 30, 2015
MYERS, Fla., Dec. 30, 2015 /PRNewswire/ — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of Clarient, Inc.
Is NeoGenomics a biotech company?
NeoGenomics: Buy And Hold This Specialist Biotech – The Gains Are Coming (NASDAQ:NEO) | Seeking Alpha.
Is NeoGenomics a good investment?
Out of 8 analysts, 3 (37.5%) are recommending NEO as a Strong Buy, 4 (50%) are recommending NEO as a Buy, 1 (12.5%) are recommending NEO as a Hold, 0 (0%) are recommending NEO as a Sell, and 0 (0%) are recommending NEO as a Strong Sell. What is NEO’s earnings growth forecast for 2022-2024?
Why is Neo stock down?
NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, sending shares down more than 20% in after-hours trading.
Will NeoGenomics stock go up?
Stock Price Forecast The 12 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 19.00, with a high estimate of 26.00 and a low estimate of 12.00. The median estimate represents a +151.66% increase from the last price of 7.55.
Will NeoGenomics recover?
NEW YORK – NeoGenomics sees 2022 as a rebuilding year while it searches for a new CEO, develops broader NGS panels, and implements initiatives to improve its laboratory processes, Executive Chair Lynn Tetrault said on a conference call Wednesday.
Should I sell NeoGenomics stock?
Should I buy or sell NeoGenomics stock right now? 10 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” NeoGenomics stock.
https://www.youtube.com/watch?v=Cqlh_cD8XA8